Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SS1P with Immune Depletion in Mesothelioma, Lung, and Pancreatic Cancer
NCT01362790Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2011
- Primary completion
- Aug 2016
- Modality
- Antibody Fragments, Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of ss1p in mesothelioma, lung adenocarcinoma and pancreatic adenocarcinoma (PDAC) (7 arms), sponsored by National Cancer Institute. Primary endpoints: Response Assessment at 52 months, Count of Participants With SS1P Antibody Formation at Day 30 and 2 more. Started May 2011; status: completed.
02
Drugs
ss1p
03
Conditions
mesotheliomalung adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01362790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362790.